nodes	percent_of_prediction	percent_of_DWPC	metapath
Trifluoperazine—TNNC1—dilated cardiomyopathy	0.744	1	CbGaD
Trifluoperazine—ABCB1—Lisinopril—dilated cardiomyopathy	0.00868	0.532	CbGbCtD
Trifluoperazine—ABCB1—Spironolactone—dilated cardiomyopathy	0.00764	0.468	CbGbCtD
Trifluoperazine—CALM1—sympathetic nervous system—dilated cardiomyopathy	0.00396	0.094	CbGeAlD
Trifluoperazine—Menstruation irregular—Spironolactone—dilated cardiomyopathy	0.0033	0.0589	CcSEcCtD
Trifluoperazine—Tetany—Furosemide—dilated cardiomyopathy	0.00305	0.0544	CcSEcCtD
Trifluoperazine—S100A4—cardiac ventricle—dilated cardiomyopathy	0.00295	0.0702	CbGeAlD
Trifluoperazine—S100A4—myocardium—dilated cardiomyopathy	0.00278	0.066	CbGeAlD
Trifluoperazine—TNNC1—cardiac ventricle—dilated cardiomyopathy	0.00248	0.059	CbGeAlD
Trifluoperazine—HTR2A—pulmonary artery—dilated cardiomyopathy	0.00248	0.0589	CbGeAlD
Trifluoperazine—EBPL—heart—dilated cardiomyopathy	0.00245	0.0583	CbGeAlD
Trifluoperazine—HTR2A—sympathetic nervous system—dilated cardiomyopathy	0.00241	0.0573	CbGeAlD
Trifluoperazine—TNNC1—myocardium—dilated cardiomyopathy	0.00234	0.0555	CbGeAlD
Trifluoperazine—Amenorrhoea—Spironolactone—dilated cardiomyopathy	0.00208	0.0371	CcSEcCtD
Trifluoperazine—S100A4—heart—dilated cardiomyopathy	0.00194	0.0461	CbGeAlD
Trifluoperazine—Moricizine—SCN5A—dilated cardiomyopathy	0.00189	0.91	CrCbGaD
Trifluoperazine—S100A4—cardiac atrium—dilated cardiomyopathy	0.00166	0.0394	CbGeAlD
Trifluoperazine—Gynaecomastia—Spironolactone—dilated cardiomyopathy	0.00164	0.0292	CcSEcCtD
Trifluoperazine—TNNC1—heart—dilated cardiomyopathy	0.00163	0.0388	CbGeAlD
Trifluoperazine—TNNC1—cardiac atrium—dilated cardiomyopathy	0.0014	0.0332	CbGeAlD
Trifluoperazine—Cholestasis—Furosemide—dilated cardiomyopathy	0.00131	0.0234	CcSEcCtD
Trifluoperazine—Glycosuria—Furosemide—dilated cardiomyopathy	0.00123	0.0219	CcSEcCtD
Trifluoperazine—Laryngeal oedema—Lisinopril—dilated cardiomyopathy	0.00116	0.0207	CcSEcCtD
Trifluoperazine—Eosinophilia—Spironolactone—dilated cardiomyopathy	0.00114	0.0202	CcSEcCtD
Trifluoperazine—CALM3—cardiac ventricle—dilated cardiomyopathy	0.00108	0.0257	CbGeAlD
Trifluoperazine—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00106	0.0188	CcSEcCtD
Trifluoperazine—Drowsiness—Spironolactone—dilated cardiomyopathy	0.00102	0.0182	CcSEcCtD
Trifluoperazine—CALM3—myocardium—dilated cardiomyopathy	0.00102	0.0242	CbGeAlD
Trifluoperazine—SIGMAR1—cardiac ventricle—dilated cardiomyopathy	0.000967	0.023	CbGeAlD
Trifluoperazine—Agranulocytosis—Spironolactone—dilated cardiomyopathy	0.000955	0.017	CcSEcCtD
Trifluoperazine—Aplastic anaemia—Furosemide—dilated cardiomyopathy	0.000934	0.0166	CcSEcCtD
Trifluoperazine—SIGMAR1—myocardium—dilated cardiomyopathy	0.00091	0.0216	CbGeAlD
Trifluoperazine—CALM2—cardiac ventricle—dilated cardiomyopathy	0.00085	0.0202	CbGeAlD
Trifluoperazine—CALM1—cardiac ventricle—dilated cardiomyopathy	0.000846	0.0201	CbGeAlD
Trifluoperazine—Photosensitivity—Furosemide—dilated cardiomyopathy	0.000822	0.0147	CcSEcCtD
Trifluoperazine—Haemolytic anaemia—Furosemide—dilated cardiomyopathy	0.0008	0.0143	CcSEcCtD
Trifluoperazine—CALM2—myocardium—dilated cardiomyopathy	0.000799	0.019	CbGeAlD
Trifluoperazine—CALM1—myocardium—dilated cardiomyopathy	0.000796	0.0189	CbGeAlD
Trifluoperazine—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.000768	0.0137	CcSEcCtD
Trifluoperazine—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.000765	0.0136	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Furosemide—dilated cardiomyopathy	0.000746	0.0133	CcSEcCtD
Trifluoperazine—Leukopenia—Spironolactone—dilated cardiomyopathy	0.000715	0.0128	CcSEcCtD
Trifluoperazine—CALM3—heart—dilated cardiomyopathy	0.00071	0.0169	CbGeAlD
Trifluoperazine—CHRM2—heart—dilated cardiomyopathy	0.0007	0.0166	CbGeAlD
Trifluoperazine—Urinary retention—Furosemide—dilated cardiomyopathy	0.000687	0.0122	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.000652	0.0116	CcSEcCtD
Trifluoperazine—Muscular weakness—Furosemide—dilated cardiomyopathy	0.000637	0.0114	CcSEcCtD
Trifluoperazine—SIGMAR1—heart—dilated cardiomyopathy	0.000635	0.0151	CbGeAlD
Trifluoperazine—Eosinophilia—Furosemide—dilated cardiomyopathy	0.000618	0.011	CcSEcCtD
Trifluoperazine—Photosensitivity—Lisinopril—dilated cardiomyopathy	0.000617	0.011	CcSEcCtD
Trifluoperazine—CALM3—cardiac atrium—dilated cardiomyopathy	0.000608	0.0144	CbGeAlD
Trifluoperazine—Eczema—Lisinopril—dilated cardiomyopathy	0.000603	0.0107	CcSEcCtD
Trifluoperazine—Haemolytic anaemia—Lisinopril—dilated cardiomyopathy	0.0006	0.0107	CcSEcCtD
Trifluoperazine—Nasal congestion—Lisinopril—dilated cardiomyopathy	0.000595	0.0106	CcSEcCtD
Trifluoperazine—Somnolence—Spironolactone—dilated cardiomyopathy	0.00058	0.0103	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00057	0.0102	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.000563	0.01	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Lisinopril—dilated cardiomyopathy	0.00056	0.00998	CcSEcCtD
Trifluoperazine—CALM2—heart—dilated cardiomyopathy	0.000558	0.0133	CbGeAlD
Trifluoperazine—Drowsiness—Furosemide—dilated cardiomyopathy	0.000556	0.00992	CcSEcCtD
Trifluoperazine—CALM1—heart—dilated cardiomyopathy	0.000555	0.0132	CbGeAlD
Trifluoperazine—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.000555	0.0099	CcSEcCtD
Trifluoperazine—SIGMAR1—cardiac atrium—dilated cardiomyopathy	0.000543	0.0129	CbGeAlD
Trifluoperazine—ADRA1A—heart—dilated cardiomyopathy	0.000523	0.0124	CbGeAlD
Trifluoperazine—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.000519	0.00926	CcSEcCtD
Trifluoperazine—Urticaria—Spironolactone—dilated cardiomyopathy	0.000518	0.00924	CcSEcCtD
Trifluoperazine—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000516	0.00919	CcSEcCtD
Trifluoperazine—Cardiac arrest—Lisinopril—dilated cardiomyopathy	0.000515	0.00918	CcSEcCtD
Trifluoperazine—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000481	0.00857	CcSEcCtD
Trifluoperazine—CALM2—cardiac atrium—dilated cardiomyopathy	0.000477	0.0113	CbGeAlD
Trifluoperazine—CALM1—cardiac atrium—dilated cardiomyopathy	0.000475	0.0113	CbGeAlD
Trifluoperazine—Asthma—Lisinopril—dilated cardiomyopathy	0.000468	0.00835	CcSEcCtD
Trifluoperazine—Eosinophilia—Lisinopril—dilated cardiomyopathy	0.000464	0.00826	CcSEcCtD
Trifluoperazine—Pruritus—Spironolactone—dilated cardiomyopathy	0.000462	0.00823	CcSEcCtD
Trifluoperazine—Bronchospasm—Lisinopril—dilated cardiomyopathy	0.000461	0.00821	CcSEcCtD
Trifluoperazine—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.000445	0.00793	CcSEcCtD
Trifluoperazine—Erythema—Furosemide—dilated cardiomyopathy	0.000435	0.00775	CcSEcCtD
Trifluoperazine—Dizziness—Spironolactone—dilated cardiomyopathy	0.000431	0.00769	CcSEcCtD
Trifluoperazine—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.000431	0.00769	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.000427	0.00762	CcSEcCtD
Trifluoperazine—Weight increased—Lisinopril—dilated cardiomyopathy	0.000426	0.0076	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.000422	0.00753	CcSEcCtD
Trifluoperazine—Muscle spasms—Furosemide—dilated cardiomyopathy	0.000418	0.00745	CcSEcCtD
Trifluoperazine—Rash—Spironolactone—dilated cardiomyopathy	0.000411	0.00733	CcSEcCtD
Trifluoperazine—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000411	0.00733	CcSEcCtD
Trifluoperazine—Vision blurred—Furosemide—dilated cardiomyopathy	0.00041	0.00731	CcSEcCtD
Trifluoperazine—Headache—Spironolactone—dilated cardiomyopathy	0.000409	0.00728	CcSEcCtD
Trifluoperazine—Jaundice—Lisinopril—dilated cardiomyopathy	0.000407	0.00725	CcSEcCtD
Trifluoperazine—Agitation—Furosemide—dilated cardiomyopathy	0.0004	0.00712	CcSEcCtD
Trifluoperazine—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.00039	0.00695	CcSEcCtD
Trifluoperazine—Leukopenia—Furosemide—dilated cardiomyopathy	0.000389	0.00694	CcSEcCtD
Trifluoperazine—Nausea—Spironolactone—dilated cardiomyopathy	0.000387	0.00691	CcSEcCtD
Trifluoperazine—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.000369	0.00658	CcSEcCtD
Trifluoperazine—Dry mouth—Furosemide—dilated cardiomyopathy	0.000362	0.00645	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.000355	0.00633	CcSEcCtD
Trifluoperazine—Skin disorder—Furosemide—dilated cardiomyopathy	0.000345	0.00615	CcSEcCtD
Trifluoperazine—HTR2A—heart—dilated cardiomyopathy	0.000338	0.00804	CbGeAlD
Trifluoperazine—Anorexia—Furosemide—dilated cardiomyopathy	0.000338	0.00603	CcSEcCtD
Trifluoperazine—Hypotension—Furosemide—dilated cardiomyopathy	0.000332	0.00591	CcSEcCtD
Trifluoperazine—Erythema—Lisinopril—dilated cardiomyopathy	0.000326	0.00582	CcSEcCtD
Trifluoperazine—Nervousness—Lisinopril—dilated cardiomyopathy	0.000317	0.00565	CcSEcCtD
Trifluoperazine—Somnolence—Furosemide—dilated cardiomyopathy	0.000316	0.00562	CcSEcCtD
Trifluoperazine—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000314	0.00559	CcSEcCtD
Trifluoperazine—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000309	0.0055	CcSEcCtD
Trifluoperazine—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000307	0.00548	CcSEcCtD
Trifluoperazine—Fatigue—Furosemide—dilated cardiomyopathy	0.000306	0.00545	CcSEcCtD
Trifluoperazine—Tremor—Lisinopril—dilated cardiomyopathy	0.000306	0.00545	CcSEcCtD
Trifluoperazine—Constipation—Furosemide—dilated cardiomyopathy	0.000303	0.00541	CcSEcCtD
Trifluoperazine—Angioedema—Lisinopril—dilated cardiomyopathy	0.000298	0.00531	CcSEcCtD
Trifluoperazine—Leukopenia—Lisinopril—dilated cardiomyopathy	0.000292	0.00521	CcSEcCtD
Trifluoperazine—Cough—Lisinopril—dilated cardiomyopathy	0.000285	0.00508	CcSEcCtD
Trifluoperazine—Urticaria—Furosemide—dilated cardiomyopathy	0.000282	0.00503	CcSEcCtD
Trifluoperazine—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000281	0.005	CcSEcCtD
Trifluoperazine—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000272	0.00484	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.000266	0.00475	CcSEcCtD
Trifluoperazine—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000261	0.00466	CcSEcCtD
Trifluoperazine—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000259	0.00461	CcSEcCtD
Trifluoperazine—Asthenia—Furosemide—dilated cardiomyopathy	0.000255	0.00454	CcSEcCtD
Trifluoperazine—Anorexia—Lisinopril—dilated cardiomyopathy	0.000254	0.00452	CcSEcCtD
Trifluoperazine—Pruritus—Furosemide—dilated cardiomyopathy	0.000251	0.00448	CcSEcCtD
Trifluoperazine—Hypotension—Lisinopril—dilated cardiomyopathy	0.000249	0.00444	CcSEcCtD
Trifluoperazine—Insomnia—Lisinopril—dilated cardiomyopathy	0.000241	0.00429	CcSEcCtD
Trifluoperazine—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000237	0.00423	CcSEcCtD
Trifluoperazine—Somnolence—Lisinopril—dilated cardiomyopathy	0.000237	0.00422	CcSEcCtD
Trifluoperazine—Dizziness—Furosemide—dilated cardiomyopathy	0.000235	0.00418	CcSEcCtD
Trifluoperazine—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000231	0.00413	CcSEcCtD
Trifluoperazine—Fatigue—Lisinopril—dilated cardiomyopathy	0.00023	0.00409	CcSEcCtD
Trifluoperazine—Constipation—Lisinopril—dilated cardiomyopathy	0.000228	0.00406	CcSEcCtD
Trifluoperazine—Rash—Furosemide—dilated cardiomyopathy	0.000224	0.00399	CcSEcCtD
Trifluoperazine—Dermatitis—Furosemide—dilated cardiomyopathy	0.000224	0.00399	CcSEcCtD
Trifluoperazine—Headache—Furosemide—dilated cardiomyopathy	0.000222	0.00396	CcSEcCtD
Trifluoperazine—ABCB1—heart—dilated cardiomyopathy	0.000222	0.00527	CbGeAlD
Trifluoperazine—Urticaria—Lisinopril—dilated cardiomyopathy	0.000212	0.00377	CcSEcCtD
Trifluoperazine—Nausea—Furosemide—dilated cardiomyopathy	0.000211	0.00376	CcSEcCtD
Trifluoperazine—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000211	0.00375	CcSEcCtD
Trifluoperazine—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000196	0.0035	CcSEcCtD
Trifluoperazine—Asthenia—Lisinopril—dilated cardiomyopathy	0.000191	0.00341	CcSEcCtD
Trifluoperazine—Pruritus—Lisinopril—dilated cardiomyopathy	0.000188	0.00336	CcSEcCtD
Trifluoperazine—Loxapine—ADRB1—dilated cardiomyopathy	0.000188	0.0904	CrCbGaD
Trifluoperazine—Dizziness—Lisinopril—dilated cardiomyopathy	0.000176	0.00314	CcSEcCtD
Trifluoperazine—Rash—Lisinopril—dilated cardiomyopathy	0.000168	0.00299	CcSEcCtD
Trifluoperazine—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000168	0.00299	CcSEcCtD
Trifluoperazine—Headache—Lisinopril—dilated cardiomyopathy	0.000167	0.00297	CcSEcCtD
Trifluoperazine—Nausea—Lisinopril—dilated cardiomyopathy	0.000158	0.00282	CcSEcCtD
Trifluoperazine—CALM3—Adaptive Immune System—RAC1—dilated cardiomyopathy	1.03e-05	7.35e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—GPCR downstream signaling—AGT—dilated cardiomyopathy	9.99e-06	7.16e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—GPCR downstream signaling—AGT—dilated cardiomyopathy	9.94e-06	7.12e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—RAC1—dilated cardiomyopathy	9.92e-06	7.11e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—RAC1—dilated cardiomyopathy	9.92e-06	7.11e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—CXCL2—dilated cardiomyopathy	9.9e-06	7.1e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—AGTR2—dilated cardiomyopathy	9.9e-06	7.1e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—CXCL2—dilated cardiomyopathy	9.85e-06	7.06e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—AGTR2—dilated cardiomyopathy	9.85e-06	7.06e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—PSEN2—dilated cardiomyopathy	9.79e-06	7.02e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—ADRB2—dilated cardiomyopathy	9.76e-06	6.99e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—PSEN2—dilated cardiomyopathy	9.64e-06	6.9e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—PSEN2—dilated cardiomyopathy	9.62e-06	6.89e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling by GPCR—RAC1—dilated cardiomyopathy	9.49e-06	6.8e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—PSEN2—dilated cardiomyopathy	9.46e-06	6.78e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling by GPCR—RAC1—dilated cardiomyopathy	9.45e-06	6.77e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—PSEN2—dilated cardiomyopathy	9.44e-06	6.76e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—AGTR1—dilated cardiomyopathy	9.25e-06	6.62e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—CXCR3—dilated cardiomyopathy	9.21e-06	6.6e-05	CbGpPWpGaD
Trifluoperazine—DRD2—GPCR downstream signaling—RAC1—dilated cardiomyopathy	9.18e-06	6.58e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—CXCR3—dilated cardiomyopathy	9.16e-06	6.56e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling by GPCR—AGT—dilated cardiomyopathy	9.07e-06	6.5e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	9.03e-06	6.47e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling by GPCR—AGT—dilated cardiomyopathy	9.03e-06	6.47e-05	CbGpPWpGaD
Trifluoperazine—HRH1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	9.01e-06	6.46e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	8.94e-06	6.41e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—AGTR1—dilated cardiomyopathy	8.94e-06	6.41e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—ADRB1—dilated cardiomyopathy	8.92e-06	6.39e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	8.91e-06	6.39e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—ADRB1—dilated cardiomyopathy	8.87e-06	6.36e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—GPCR downstream signaling—RAC1—dilated cardiomyopathy	8.87e-06	6.35e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	8.84e-06	6.34e-05	CbGpPWpGaD
Trifluoperazine—DRD2—GPCR downstream signaling—AGT—dilated cardiomyopathy	8.77e-06	6.28e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—ADRB2—dilated cardiomyopathy	8.77e-06	6.28e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—CXCL2—dilated cardiomyopathy	8.7e-06	6.23e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—AGTR2—dilated cardiomyopathy	8.7e-06	6.23e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—GPCR downstream signaling—AGT—dilated cardiomyopathy	8.63e-06	6.18e-05	CbGpPWpGaD
Trifluoperazine—HRH1—GPCR downstream signaling—AGT—dilated cardiomyopathy	8.61e-06	6.17e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—AGTR2—dilated cardiomyopathy	8.56e-06	6.13e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—CXCL2—dilated cardiomyopathy	8.56e-06	6.13e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—CXCL2—dilated cardiomyopathy	8.54e-06	6.12e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—AGTR2—dilated cardiomyopathy	8.54e-06	6.12e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by NGF—EGFR—dilated cardiomyopathy	8.52e-06	6.1e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling by GPCR—RAF1—dilated cardiomyopathy	8.51e-06	6.09e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	8.49e-06	6.08e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—ADRB2—dilated cardiomyopathy	8.48e-06	6.08e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	8.48e-06	6.08e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—GPCR downstream signaling—AGT—dilated cardiomyopathy	8.47e-06	6.07e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—GPCR downstream signaling—AGT—dilated cardiomyopathy	8.45e-06	6.06e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—AGTR2—dilated cardiomyopathy	8.4e-06	6.02e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—CXCL2—dilated cardiomyopathy	8.4e-06	6.02e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	8.39e-06	6.01e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—CXCL2—dilated cardiomyopathy	8.38e-06	6e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—AGTR2—dilated cardiomyopathy	8.38e-06	6e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—RAC1—dilated cardiomyopathy	8.34e-06	5.97e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by NGF—EGFR—dilated cardiomyopathy	8.24e-06	5.9e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by NGF—EGFR—dilated cardiomyopathy	8.24e-06	5.9e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—RAC1—dilated cardiomyopathy	8.2e-06	5.88e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—RAC1—dilated cardiomyopathy	8.19e-06	5.86e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—CXCR3—dilated cardiomyopathy	8.08e-06	5.79e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—RAC1—dilated cardiomyopathy	8.05e-06	5.77e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—RAC1—dilated cardiomyopathy	8.03e-06	5.76e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—PSEN2—dilated cardiomyopathy	8e-06	5.73e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—AGT—dilated cardiomyopathy	7.97e-06	5.71e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—CXCR3—dilated cardiomyopathy	7.95e-06	5.7e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—CXCR3—dilated cardiomyopathy	7.94e-06	5.69e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Hemostasis—RAF1—dilated cardiomyopathy	7.87e-06	5.64e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—AGT—dilated cardiomyopathy	7.84e-06	5.62e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.83e-06	5.61e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—AGT—dilated cardiomyopathy	7.82e-06	5.6e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—CXCR3—dilated cardiomyopathy	7.81e-06	5.6e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—CXCR3—dilated cardiomyopathy	7.79e-06	5.58e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—ITGB1—dilated cardiomyopathy	7.74e-06	5.55e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—PSEN2—dilated cardiomyopathy	7.74e-06	5.54e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—PSEN2—dilated cardiomyopathy	7.74e-06	5.54e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.7e-06	5.52e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—AGT—dilated cardiomyopathy	7.7e-06	5.51e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.69e-06	5.51e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—AGT—dilated cardiomyopathy	7.67e-06	5.5e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—AGTR1—dilated cardiomyopathy	7.62e-06	5.46e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Hemostasis—RAF1—dilated cardiomyopathy	7.61e-06	5.45e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Hemostasis—RAF1—dilated cardiomyopathy	7.61e-06	5.45e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—RAC1—dilated cardiomyopathy	7.58e-06	5.43e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—AGTR1—dilated cardiomyopathy	7.58e-06	5.43e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.56e-06	5.42e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.54e-06	5.4e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—ITGB1—dilated cardiomyopathy	7.49e-06	5.36e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—ITGB1—dilated cardiomyopathy	7.49e-06	5.36e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—AGT—dilated cardiomyopathy	7.24e-06	5.19e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—ADRB2—dilated cardiomyopathy	7.22e-06	5.18e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—ADRB2—dilated cardiomyopathy	7.19e-06	5.15e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	7.12e-06	5.1e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CXCL2—dilated cardiomyopathy	7.1e-06	5.09e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—AGTR2—dilated cardiomyopathy	7.1e-06	5.09e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Innate Immune System—RAF1—dilated cardiomyopathy	7.08e-06	5.08e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	6.93e-06	4.97e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—AGTR2—dilated cardiomyopathy	6.87e-06	4.92e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CXCL2—dilated cardiomyopathy	6.87e-06	4.92e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CXCL2—dilated cardiomyopathy	6.87e-06	4.92e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—AGTR2—dilated cardiomyopathy	6.87e-06	4.92e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Innate Immune System—RAF1—dilated cardiomyopathy	6.85e-06	4.91e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Innate Immune System—RAF1—dilated cardiomyopathy	6.85e-06	4.91e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—RAC1—dilated cardiomyopathy	6.81e-06	4.88e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Adaptive Immune System—RAF1—dilated cardiomyopathy	6.8e-06	4.87e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.69e-06	4.79e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CXCR3—dilated cardiomyopathy	6.6e-06	4.73e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—CD36—dilated cardiomyopathy	6.6e-06	4.73e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—RAC1—dilated cardiomyopathy	6.59e-06	4.72e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—RAC1—dilated cardiomyopathy	6.59e-06	4.72e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—RAF1—dilated cardiomyopathy	6.58e-06	4.71e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—RAF1—dilated cardiomyopathy	6.58e-06	4.71e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.58e-06	4.71e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.57e-06	4.7e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—AGT—dilated cardiomyopathy	6.51e-06	4.66e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.46e-06	4.63e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.44e-06	4.62e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—ADRB1—dilated cardiomyopathy	6.39e-06	4.58e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CXCR3—dilated cardiomyopathy	6.39e-06	4.58e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CXCR3—dilated cardiomyopathy	6.39e-06	4.58e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—CD36—dilated cardiomyopathy	6.39e-06	4.58e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—CD36—dilated cardiomyopathy	6.39e-06	4.58e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—ADRB2—dilated cardiomyopathy	6.34e-06	4.55e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling by GPCR—RAF1—dilated cardiomyopathy	6.3e-06	4.51e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—AGT—dilated cardiomyopathy	6.29e-06	4.51e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—AGT—dilated cardiomyopathy	6.29e-06	4.51e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling by GPCR—RAF1—dilated cardiomyopathy	6.26e-06	4.49e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	6.24e-06	4.47e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—ADRB2—dilated cardiomyopathy	6.24e-06	4.47e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—ADRB2—dilated cardiomyopathy	6.23e-06	4.46e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—RAC1—dilated cardiomyopathy	6.22e-06	4.46e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	6.21e-06	4.45e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—ADRB1—dilated cardiomyopathy	6.19e-06	4.43e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—ADRB1—dilated cardiomyopathy	6.19e-06	4.43e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	6.18e-06	4.43e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—ADRB2—dilated cardiomyopathy	6.13e-06	4.39e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—ADRB2—dilated cardiomyopathy	6.11e-06	4.38e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—RAC1—dilated cardiomyopathy	6.02e-06	4.31e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—RAC1—dilated cardiomyopathy	6.02e-06	4.31e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling by GPCR—EGFR—dilated cardiomyopathy	5.83e-06	4.18e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—RAC1—dilated cardiomyopathy	5.74e-06	4.12e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—RAC1—dilated cardiomyopathy	5.61e-06	4.02e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—RAC1—dilated cardiomyopathy	5.58e-06	4e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—RAC1—dilated cardiomyopathy	5.56e-06	3.98e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—RAC1—dilated cardiomyopathy	5.56e-06	3.98e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.53e-06	3.96e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.46e-06	3.91e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.45e-06	3.91e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.44e-06	3.9e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.43e-06	3.89e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.36e-06	3.84e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—AGT—dilated cardiomyopathy	5.36e-06	3.84e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.35e-06	3.83e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.34e-06	3.83e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—AGT—dilated cardiomyopathy	5.33e-06	3.82e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.33e-06	3.82e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.28e-06	3.79e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.28e-06	3.79e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.27e-06	3.77e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.25e-06	3.76e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—GPX1—dilated cardiomyopathy	5.24e-06	3.76e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.18e-06	3.71e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	5.16e-06	3.7e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—CD36—dilated cardiomyopathy	5.1e-06	3.66e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—GPX1—dilated cardiomyopathy	5.07e-06	3.63e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—GPX1—dilated cardiomyopathy	5.07e-06	3.63e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—RAF1—dilated cardiomyopathy	5.02e-06	3.6e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.01e-06	3.59e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.01e-06	3.59e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—CD36—dilated cardiomyopathy	4.94e-06	3.54e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—CD36—dilated cardiomyopathy	4.94e-06	3.54e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—RAC1—dilated cardiomyopathy	4.92e-06	3.53e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Innate Immune System—EGFR—dilated cardiomyopathy	4.86e-06	3.48e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—RAC1—dilated cardiomyopathy	4.85e-06	3.47e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—RAC1—dilated cardiomyopathy	4.84e-06	3.46e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—RAC1—dilated cardiomyopathy	4.76e-06	3.41e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—RAC1—dilated cardiomyopathy	4.74e-06	3.4e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—AGT—dilated cardiomyopathy	4.71e-06	3.37e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Innate Immune System—EGFR—dilated cardiomyopathy	4.7e-06	3.37e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Innate Immune System—EGFR—dilated cardiomyopathy	4.7e-06	3.37e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Adaptive Immune System—EGFR—dilated cardiomyopathy	4.66e-06	3.34e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—AGT—dilated cardiomyopathy	4.63e-06	3.32e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—AGT—dilated cardiomyopathy	4.62e-06	3.31e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—AGT—dilated cardiomyopathy	4.6e-06	3.29e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—AGT—dilated cardiomyopathy	4.55e-06	3.26e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—AGT—dilated cardiomyopathy	4.53e-06	3.25e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.52e-06	3.24e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—EGFR—dilated cardiomyopathy	4.51e-06	3.23e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—EGFR—dilated cardiomyopathy	4.51e-06	3.23e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.45e-06	3.19e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—AGT—dilated cardiomyopathy	4.45e-06	3.19e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—AGT—dilated cardiomyopathy	4.45e-06	3.19e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.37e-06	3.13e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.37e-06	3.13e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling by GPCR—EGFR—dilated cardiomyopathy	4.32e-06	3.09e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.31e-06	3.09e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.31e-06	3.09e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling by GPCR—EGFR—dilated cardiomyopathy	4.3e-06	3.08e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—RAF1—dilated cardiomyopathy	4.13e-06	2.96e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—RAC1—dilated cardiomyopathy	4.02e-06	2.88e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—RAF1—dilated cardiomyopathy	3.99e-06	2.86e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—RAF1—dilated cardiomyopathy	3.99e-06	2.86e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	3.97e-06	2.85e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—RAC1—dilated cardiomyopathy	3.89e-06	2.79e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—RAC1—dilated cardiomyopathy	3.89e-06	2.79e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—CD36—dilated cardiomyopathy	3.87e-06	2.77e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—AGT—dilated cardiomyopathy	3.84e-06	2.75e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—RAF1—dilated cardiomyopathy	3.81e-06	2.73e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.79e-06	2.72e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.73e-06	2.67e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.72e-06	2.67e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—RAF1—dilated cardiomyopathy	3.72e-06	2.66e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—AGT—dilated cardiomyopathy	3.72e-06	2.66e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—AGT—dilated cardiomyopathy	3.72e-06	2.66e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—RAF1—dilated cardiomyopathy	3.7e-06	2.65e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—RAF1—dilated cardiomyopathy	3.68e-06	2.64e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—RAF1—dilated cardiomyopathy	3.68e-06	2.64e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.66e-06	2.62e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.65e-06	2.62e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—AGT—dilated cardiomyopathy	3.48e-06	2.5e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—EGFR—dilated cardiomyopathy	3.45e-06	2.47e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—RAF1—dilated cardiomyopathy	3.27e-06	2.34e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—RAF1—dilated cardiomyopathy	3.21e-06	2.3e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—RAF1—dilated cardiomyopathy	3.21e-06	2.3e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	3.17e-06	2.27e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—RAF1—dilated cardiomyopathy	3.15e-06	2.26e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—RAF1—dilated cardiomyopathy	3.15e-06	2.25e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.1e-06	2.22e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	3.09e-06	2.21e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—EGFR—dilated cardiomyopathy	3e-06	2.15e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—EGFR—dilated cardiomyopathy	3e-06	2.15e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—EGFR—dilated cardiomyopathy	2.83e-06	2.03e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	2.78e-06	1.99e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—EGFR—dilated cardiomyopathy	2.74e-06	1.96e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—EGFR—dilated cardiomyopathy	2.74e-06	1.96e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—RAF1—dilated cardiomyopathy	2.67e-06	1.91e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—EGFR—dilated cardiomyopathy	2.61e-06	1.87e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—RAF1—dilated cardiomyopathy	2.58e-06	1.85e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—RAF1—dilated cardiomyopathy	2.58e-06	1.85e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—EGFR—dilated cardiomyopathy	2.55e-06	1.83e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—EGFR—dilated cardiomyopathy	2.54e-06	1.82e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—EGFR—dilated cardiomyopathy	2.53e-06	1.81e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—EGFR—dilated cardiomyopathy	2.53e-06	1.81e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—EGFR—dilated cardiomyopathy	2.24e-06	1.6e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—EGFR—dilated cardiomyopathy	2.2e-06	1.58e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—EGFR—dilated cardiomyopathy	2.2e-06	1.58e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—EGFR—dilated cardiomyopathy	2.16e-06	1.55e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—EGFR—dilated cardiomyopathy	2.16e-06	1.55e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—EGFR—dilated cardiomyopathy	1.83e-06	1.31e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—EGFR—dilated cardiomyopathy	1.77e-06	1.27e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.77e-06	1.27e-05	CbGpPWpGaD
